Adaptimmune Therapeutics
ADAP
$1.19
Share price
-1.65%
Change (1 day)
-13.14%
Change (1 year)
Categories
Operating Margin for Adaptimmune Therapeutics (ADAP)
Operating Margin as of May 2024 (TTM): -603.96%
According to Adaptimmune Therapeutics's latest financial reports and stock price the company's current Operating Margin is -603.96%. At the end of 2021 the company had an Operating Margin of -2,558.12%.
Operating Margin history for Adaptimmune Therapeutics from 2016 to 2022
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2021 | -2,558.12% | -22.07% |
| 2020 | -3,282.72% | -73.1% |
| 2019 | -12,203.48% | 7542.5% |
| 2018 | -159.68% | -13.31% |
| 2017 | -184.20% | -63% |
| 2016 | -497.87% | 125.28% |
| 2015 | -221.00% | -90.7% |
| 2014 | -2,377.46% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin differencediff. | Country |
|---|---|---|---|
 uniQure QURE | -120.45% | -80.06% | 🇳🇱 Netherlands |
 Novavax NVAX | -149.57% | -75.24% | 🇺🇸 USA |
 Exelixis EXEL | 11.86% | -101.96% | 🇺🇸 USA |
 Enzo Biochem ENZ | -43.44% | -92.81% | 🇺🇸 USA |
What is a company's Operating Margin
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.